{"title": "", "body": "in Haemophilus influenzae infection, 1862b-1863b in health care-associated pneumonia, 595, 595b-596b in Helicobacter pylori infection, 892, 892t hepatic function and, 1765 hepatotoxicity of, 981 in hospital-acquired pneumonia, 595b-596b, 595t in infective endocarditis, 468b-471b, 470t-471t in inflammatory bowel disease, 918 interchangeability of, 1768 interstitial lung disease with, 558t in intestinal bacterial overgrowth, 904b ketolide, 1807t-1811t, 1812 1807t-1811t, -1813 1807t-1811t, \u03b2-lactam, 1807t-1811t, 1808 1807t-1811t, , 1814t in Legionnaires' disease, 1905b 1807t-1811t, -1906b 1807t-1811t, , 1906t in leprosy, 1953b 1807t-1811t, -1954b 1807t-1811t, in leptospirosis, 1938b 1807t-1811t, lincosamide, 1809t-1811t linezolid, 1807t-1808t, 1812 1807t-1811t, -1813 in listeriosis, 1836b after lung transplantation, 620 in Lyme disease, 1934b Lyme disease, , 1935t macrolide, 1807t-1811t, 1812 Lyme disease, -1813 mechanism of action of, 1806, 1807t in meningitis, 1854b, 2361b-2365b, 2362t-2363t minimal inhibitory concentration of, 1804, 1805f monitoring of, 1767 in Moraxella catarrhalis infection, 1864b in mycetoma, 2007b in Mycoplasma pneumoniae infection, 1916b in nocardiosis, 1971b in non-spore-forming anaerobic bacterial infection, 1849b-1850b, 1850t occupation and, 1765 in osteomyelitis, 1736b, 1736t penicillin, 1807t-1811t, 1808, 1814t in peritonitis, 926b, 926t in pertussis, 1902b pharmacodynamics of, 1767 pharmacokinetics of, 1806-1807 in pharyngitis, 2469 in plague, 1898b in pneumonia, 591b-593b, 592t in post-liver transplantation infection, 1010-1011 in pregnancy, 1764 prophylactic in adult congenital heart disease, 408 in infective endocarditis, 472, 472t-473t in Neisseria meningitidis infection, 1854-1855, 1854t, 2365 for surgery, 1785 in urinary tract infection prevention, 1796 in prostatitis, 810b in psittacosis, 1922b in pyogenic liver abscess, 989b in Q fever, 1963b quinolone, 1807t-1811t, 1812, 1814t quinupristin/dalfopristin, 1807t-1811t, 1813 in relapsing fever, 1936b renal function and, 1765 resistance to, 1762, 1781-1782, 1782t, 1783f, 1803, 1805-1806 1763-1764, 1804 in syphilis, 1927b-1928b, 1928t tetracycline, 1807t-1811t, 1812-1813, 1814t topical, 2511 toxicity of, 1813, 1814t in trachoma, 1918b in tularemia, 1895b in typhoid fever, 1887 in typhus, 1960b in urinary tract infection, 1794b-1795b, 1795t vancomycin, 1807t-1811t, 1813 in ventilator-associated pneumonia, 595b-596b, 595t in women of reproductive potential, 1550t in yersiniosis, 1900b Antibiotics. See Antibacterial agents Antibody (antibodies), 217. See also Immune system; Immunoglobulin(s) acetylcholine receptor, 2418-2420, 2419f anticardiolipin, 1144 antineutrophil cytoplasmic, 713, 768, 1655, 1722, 1725 antinuclear, 1653-1655, 1654t in Anticonvulsants, 2291-2292, 2292t in alcohol dependence treatment, 152t central nervous system effects of, 672t discontinuation of, 2293 hepatotoxicity of, 981, 983 in pain, 135-137, 136t weight gain with, 1413t Antidepressants, 2237b-2238b, 2239t\n\ncentral nervous system effects of, 672t in irritable bowel syndrome, 871t, 872 metabolism of, genetic factors in, 187t in multiple sclerosis, 2353 preoperative, 2478t in pruritus, 2502t toxic ingestion of, 674t-677t weight gain with, 1413t in women of reproductive potential, 1551 Antidiarrheal agents, 912b-913b Antidiuresis, 1445 Antidiuretic hormone (ADH). See also Vasopressin syndrome of inappropriate secretion of, 730, 730t, 731f, 1446 cancer-related, 1191-1192 drug-induced, 2495 Antidotes. See also Antitoxin; Antivenom in acute poisoning, 679, 679t-683t Antiemetic agents, 842b, 843t-844t during chemotherapy, 1167-1177 in gastroparesis, 865b-866b Antiepileptic agents. See Anticonvulsants Antifreeze. See Ethylene glycol Antifungal agents, 1971 Antifungal agents, -1977 Antifungal agents, amphotericin B-based, 1971 Antifungal agents, -1973 Antifungal agents, in aspergillosis, 1993b Antifungal agents, -1994b Antifungal agents, , 1993t azole, 1973 Antifungal agents, -1976 Antifungal agents, in blastomycosis, 1982b Antifungal agents, in candidiasis, 1989b Antifungal agents, -1990b Antifungal agents, in coccidioidomycosis, 1981b Antifungal agents, combinations of, 1976 Antifungal agents, -1977 Antifungal agents, in cryptococcosis, 1984b Antifungal agents, -1985b Antifungal agents, in cutaneous infection, 2511 Antifungal agents, -2512 Antifungal agents, in dematiaceous fungal infection, 2008b Antifungal agents, echinocandin, 1976 Antifungal agents, flucytosine, 1973 Antifungal agents, in histoplasmosis, 1978b Antifungal agents, -1979b Antifungal agents, in mucormycosis, 1997 Antifungal agents, in mycetoma, 2007b Antifungal agents, in paracoccidioidomycosis, 1983b Antifungal agents, prophylactic, 1990 in sporotrichosis, 1986b Antigen-presenting cell, in allergic rhinitis, 1623 Antigen processing, 218, 218f Antiglobulin (Coombs) test, 1048 Antihistamines in allergic rhinitis, 1626 central nervous system effects of, 672t in mastocytosis, 1644 in pruritus, 2512-2513, 2512t in urticaria, 1630-1631 weight gain with, 1413t Antihypertensive agents, 381-385, 382t-383t.\n\nSee also Hypertension in acute severe hypertension, 387-388, 387f, 388t in chronic kidney disease, 386-388 in diabetes, 386 drug interactions with, 384-385 estrogen replacement and, 387 in heart failure, 306f-307f intravenous, 387-388, 388t in ischemic heart disease, 387 in minority populations, 386 in older persons, 386 oral contraceptives and, 387 in pregnancy, 387, 1558b in resistant hypertension, 387 selection of, 385-389, 385t, 386f in stroke prevention, 386-387 in uncomplicated primary hypertension, 385-386, 385t weight gain with, 1413t Antileukotrienes, in asthma, 535 Antimalarial agents, 2016b-2017b, 2016t, 2511\n\nAntibacterial agents (Continued) Antibacterial agents (Continued) Antibacterial agents (Continued) Antispasmodics, in irritable bowel syndrome, 871 Antistreptolysin O test, 1827 Antithrombin, 1121 -1122 Antithrombin III deficiency, 1149 -1153 in antiphospholipid antibody syndrome, 1144b direct factor Xa inhibitors in, 174 direct thrombin inhibitors in, 173-174 fibrinolytic agents in, 176-177 guidelines for, 175t-176t heparin in, 172-173, 173t platelet-active drugs in, 174-176, 174f vitamin K antagonists in, 171-172, 172f, 172t, 200-201 Antithymocyte globulin, in aplastic anemia, 1089 Antitoxin anthrax, 1839, 1839b botulism, 1845b diphtheria, 1834b, 1834t \u03b1 1 -Antitrypsin deficiency of, 985, 986f genetics of, 185t, 538, 985 serum, 540 stool, 912 Antituberculous agents, 1809t-1811t, 1945b -1946b , 1947t in nontuberculous Mycobacterium spp. infection, 1950b in coral snake envenomation, 696 in marine organism envenomation, 698t in pit viper envenomation, Gout in hemochromatosis, 1750 Gout in hemochromatosis, , 1750f in hemoglobinopathy, 1748 Gout in hemochromatosis, in hemophilia, 1138 Gout in hemochromatosis, , 1138f, 1748 Gout in hemochromatosis, in hyperlipoproteinemia, 1749 in hypertrophic osteoarthropathy, 1749, 1750f in hypogammaglobulinemia, 1749 laboratory testing in, 1652 -1653 , 1652t, 1653f in leukemia, 1750 Lyme, 1734 , 1932 , 1934 Aspergilloma, 1991 , 1991f, 1994 Aspergillosis, 1990 -1994 allergic, 1991 -1992 , 1991t diagnosis of, 1992 -1993 treatment of, 1994 alveolar, 1992 auditory canal, 1991 bronchopulmonary, allergic, 1991 -1992 , 1991t bronchiectasis in, 548-549, 550f diagnosis of, 1992 -1993 , 1993f treatment of, 1994 chronic, 1991t, 1994 clinical manifestations of, 1990 CNS, 1991 definition of, 1990 diagnosis of, 1991f-1992f, 1992 disseminated, 1991 endocardial, 1991 epidemiology of, 1990 invasive, 1990 -1991 , 1991t, 1992f diagnosis of, 1992 treatment of, 1993 , 1993t prevention of, 1994 prognosis for, 1994 pulmonary, 591, 1990 -1991 cavitary, 1991 chronic, 1991 necrotizing, 1991 sinus, 1991 -1992 treatment of, 1975 , 1993 -1994 in ST segment elevation MI, [438] [439] 442, [446] [447] [448] 447t in stable myocardial ischemia, 419 Assisted reproductive technologies, 1545 Assisted suicide, 7-8, 7t Association study, [197] [198] [199] Astemizole, 2512t Asterixis, 955 Asthma, 531-537 acetylcholine in, 531 aspirin-exacerbated, 536 blood gas analysis in, 533 bronchiectasis in, 548 C. pneumoniae infection and chest radiography in, 533 clinical manifestations of, 532 vs. COPD, 540 definition of, 531 diagnosis of, 533, 533t, 1613 in pregnancy, 1562 differential diagnosis of, 533 electrocardiography in, 533 in emergency department, 536 eosinophilia in, 533 epidemiology of, 531-536 exhaled nitric oxide in, 533 genetics of, 531 heart failure and, 314-315 histamine in, 531 immunoglobulin E in, 533 irritant-induced, 569 leukotrienes in, 531-532 lipoxins in, 531-532 mediators of, 531-532 nitric oxide in, 532 occupation and, 76, 76t, 532, 567, 568t-569t, 569, 570f in older adults, 99t pathobiology of, 531 pathology of, 531 patient history in, 532 physical examination in, 532-533, 1613 physiologic changes in, 532, 532f in pregnancy, 536, 1561 preoperative assessment of, 2481 prognosis for, 536 pulmonary function tests in, 525t, 533, 533t respiratory failure in, 643-644 severe, 528t sputum examination in, 533 status, 536 thoracic examination in, 532-533 treatment of, 533b-536b, 534f\n\n\u03b2-adrenergic agonists in, 534-535 anticholinergics in, 534-535 antileukotrienes in, 535 in aspirin-exacerbated disease, 536 control-driven, 536 corticosteroids in, 535, 535t cromolyn sodium in, 536 in emergency department, 536 immunization in, 536 long-acting \u03b2-adrenergic agonists in, 535 mepolizumab in, 535 monoclonal antibodies in, 535 omalizumab in, 535 in pregnancy, 536 radio frequency smooth muscle ablation in, 536 in respiratory failure, 643-644 in status disease, 536 theophylline in, 535 vital signs in, 532 in women of reproductive potential, 1550t work-exacerbated, 569 work-related, 532, 567, 568t, 570f diagnosis of, 570f sensitizer-induced, 567, 568t-569t Astigmatism, 2428 Astrakhan fever, 1956t, 1958 infection, 1907 -1908 , 1907t-1909t, 1910 Bartonella henselae infection, 1906 , 1907t-1909t, 1908 , 1910 , 1965t-1966t hepatic, 995-996, 1908t-1909t, 1909 -1910 Bartonella quintana infection, 1907 -1908 , 1907f, 1907t-1909t, 1910 Bartonella spp. infection, 1906 -1911 definition of, 1906 diagnosis of, 1909 , 1909t differential diagnosis of, 1910 endocardial, 468t, 1907t-1908t, 1908 , 1910 epidemiology of, 1907 , 1907t HIV infection and, 2210 prevention of, 1910 , 2192t-2193t prognosis for, 1910 -1911 treatment of, 1910b vasculoproliferative, 1909 Bartter's syndrome, 739 North American, 1981 -1982 clinical manifestations of, 1981 -1982 definition of, 1981 diagnosis of, 1982 disseminated, 1981 -1982 epidemiology of, 1981 pathobiology of, 1981 prognosis for, 1982 pulmonary, 1981 treatment of, 1982b South American, 1982 -1983 clinical manifestations of, 1982 definition of, 1982 -1983 1996 nocardial, 1970, 1971f non-spore-forming anaerobic bacteria in, 1848 pathobiology of, 2371 prognosis for, 2372-2373, 2373t staphylococcal, 1818 toxoplasmic, 2032-2033, 2034f , 1987 -1989 Candidiasis, 1986 -1990 blood stream, 1987 -1989 clinical manifestations of, 1987 definition of, 1986 -1990 diagnosis of, 1989 disseminated, 1987 -1989 , 1988f endocardial, 1988 epidemiology of, 1986 esophageal, 884, 885f, 1987 , 2198 focal, 1988 -1990 hepatosplenic, 989, 1988 , 1988f HIV infection and, 1987 , 2192t-2193t, 2198 , 2210 meningeal, 1988 -1989 mucocutaneous, 1987 , 1987f-1988f, 2451 -2452 , 2508 -2509 in autoimmune polyglandular syndrome type 1, 1508 , 1508t chronic, 1987 vs. hairy leukoplakia, 2135 -2136 treatment of, 1989 in neutropenic host, 1779 , 1987 ophthalmic, 1988 -1990 oropharyngeal, 1987 , 1989 -1990 , 2470 osteoarticular, 1988 -1990 pathobiology of, 1987 peritoneal, 1988 -1990 pharyngeal, 2470 prevention of, 1990 , 2192t-2193t prognosis for, 1990 retinal, 1988f, 1989 -1990 treatment of, 1975 , 1989b -1990b urinary tract, 1988 -1990 vulvovaginal, 1798 -1799 , 1987 , 1989 -1990 Canker sores, 2449 , 2012 -2013 , 2023b -2025b in United States, 2022 Chalazion, 2431 , 2431f Chancre, 1798 , 1923 -1924 , 1923f, 2546 Chest pain, 246, 247t, 414, 415f, [434] [435] 270-271, 271f in Chagas' disease, 2022f in chronic cough, 512 in coccidioidomycosis, 1980 in cryptococcosis, 2203f in cryptogenic organizing pneumonia, 563 decreased lung volumes on, 559t in desquamative interstitial pneumonia, 562-563 diffuse alveolar damage on, 517, 517f in diffuse alveolar hemorrhage, 554 in diffuse lung disease, 517-520, 517f-518f, 517t diffuse pleural thickening on, 521 disease distribution on, 519-520, 520f, 520t ground-glass opacity on, 517, 518f in heart failure, 301 heart size on, 265, 265f hilar adenopathy on, 559t in HIV-infected patient, 2202-2203, 2202f-2206f in Hodgkin's lymphoma, 1231f honeycombing on, 518, 559t in hypersensitivity pneumonitis, 565 in idiopathic interstitial pneumonia, 559t increased lung volumes on, 559t in infective endocarditis, 466 in interstitial lung disease, 558, 559t in Kaposi's sarcoma, 2203, 2204f Kerley A lines on, 517-518, 518f Kerley B lines on, 517-518 Kerley C lines on, 517-518 in Langerhans cell histiocytosis, 566 large opacities on, 517f-518f, 517t in Legionnaires' disease, 1905 linear patterns on, 517-518, 518f in lipoid pneumonia, 580 in lung cancer, 1268 lung volume on, 519, 519f, 519t lymph nodes on, 520, 520t in lymphoid and lymphocytic interstitial pneumonia, 563-564 malignant pleural disease on, 521 mediastinal adenopathy on, 559t mediastinal stripes on, 522f in mediastinal teratoma, 522f micronodules on, 517, 559t migratory infiltrates on, 559t in mitral regurgitation, 454t, 459 in mitral stenosis, 454t, 457 in Mycoplasma pneumoniae infection, 1914 infection, , 1914f in nocardiosis, 1970 infection, in nonspecific interstitial pneumonia, 562 in nontuberculous Mycobacterium spp. infection, 1949 in pleural disease, 520-521, 521f, 559t in pleural effusion, 608, 608f pleural plaques on, 521, 521f in Pneumocystis jiroveci pneumonia, 1999, 2000f, 2203, 2203f in pneumonia, 590, 590f in pneumothorax, 521, 521f, 559t, 611, 611f portable, 271, 516 in psittacosis, 1921-1922 in pulmonary alveolar proteinosis, 553, 553f in pulmonary arterial hypertension, 270 in pulmonary edema, 269-270, 270f, 517, 518f in pulmonary hypertension, 392, 393f pulmonary nodules on, 520, 520f pulmonary vasculature on, 268-271, 270f in pyogenic liver abscess, 989 recurrent infiltrates on, 559t in respiratory bronchiolitis-associated interstitial lung disease, 562 reticular patterns on, 518, 518f retrosternal clear space on, 265 in rheumatoid arthritis, 1686, 1686f in sarcoidosis, 582-583, 582f, 583t septal thickening on, 559t in silicosis, 573, 573f small opacities on, 517-519, 518t in sporotrichosis, [1985] [1986] in ST segment elevation MI, 437 in subpulmonic effusion, 521 in systemic sclerosis, 1710 in tetralogy of Fallot, 406, 406f in trauma, 689, 689f in tuberculosis, 590, 590f, 1941 Fallot, 406, 406f in trauma, 689, 689f in tuberculosis, 590, 590f, , 1942f-1943f, 2202 Fallot, 406, 406f in trauma, 689, 689f in tuberculosis, 590, 590f, -2203 1389 -1390 , 1390f, 1390t Reye's syndrome in, 983 Chimera, 190 Chinese traditional medicine, 178 Chlamydia trachomatis infection, 1917 , 1917t cervical, 1919 , 1919f conjunctival, 1918 , 1920 , 2434 , 2434t diagnosis of, 1920 epididymal, 1919 lymphatic, 1920 natural history of, 1920 neonatal, 1920 oropharyngeal, 1920 pelvic, 1919 -1920 in pregnancy, 1920 prevention of, 1921 reactive arthritis in, 1920 rectal, 1920 sexually transmitted, 1918 , 1919f treatment of, 1921b urethral, 1918 -1919 , 1919f Chlamydiae infection, 1916 -1922 in adolescents, 62 definition of, 1916 pathobiology of, 1917 , 1917f reactive arthritis and, 1694 screening for, 55 Chlamydophila pneumoniae infection, 1917t, 1921 Chlamydophila psittaci infection, 468t, 1219 , 1917t, 1921 -1922 , 1979 , -1981 , clinical manifestations of, 1979t, 1980 , definition of, 1979 , -1981 , diagnosis of, 1980 , epidemiology of, 1979 , extrapulmonary, 1980 , hepatic, 990 HIV infection and, 1980 , , 2191t-2192t pathobiology of, 1980 , prognosis for, 1981 , pulmonary, 1980 , , 1980f treatment of, 1981b bacterial, 2434, 2434t, 2435f in cat-scratch disease, 1908 chlamydial, 1918, 1920, 2434, -number variation, 189, 189f, 191-192, 193f-194f, 199 1984 , 2204 Cryptococcosis, 1983 -1985 clinical manifestations of, 1984 CNS, 1975 , 1984 -1985 cutaneous, 1984 definition of, 1983 -1985 diagnosis of, 1984 , 2204 epidemiology of, 1983 hepatic, 990 HIV infection and, 2210 , 2222t, 2223 meningeal, 1975 , 1984 -1985 pathobiology of, 1983 -1984 prognosis for, 1985 pulmonary, 1984 -1985 , 2203 , 2203f treatment of, 1984b -1985b 1961t, 1962 Ehrlichia chaffeensis infection, 1961 -1962 , 1961t Ehrlichia ewingii infection, 1962 , 1965t-1966t Ehrlichioses, 1960 -1962 definition of, 1960 granulocytic, 1961 , 1961t, 1962f monocytic, 1961 -1962 , 1974 -1975 adverse effects of, 1975 in AIDS, 1975 in candidiasis, 1975 , 1989b -1990b in coccidioidomycosis, 1981b in cryptococcal meningitis, 1975 drug interactions with, 1975 formulations of, 1974 in hepatosplenic candidiasis, 990b in neutropenia, 1975 Flucytosine, 1973 in cryptococcosis, 1984b -1985b , [192] [193] [189] [190] 195 familial aggregation of, 195 mutation and, [190] [191] [192] 191f studies of, [197] [198] 2, [184] [185] [186] [187] 192 Heterozygosity, 191, [195] [196] 196t Heubner 1951f, 1952 1951f, clinical examination in, 1953 1951f, clinical manifestations of, 1952 1951f, , 1952f, 2394 1951f, , 2407 1951f, -2408 1951f, definition of, 1950 1951f, diagnosis of, 1953 1951f, epidemiology of, 1951 1951f, genetics of, 1951 1951f, -1952 1951f, HIV infection and, 1953 1951f, , 2222t, 2223 1951f, immunology of, 1951 1951f, , 1951f lepromatous, 1951f-1952f, 1952 1951f, , 2540 2540f nerve damage of, 1951 orchitis with, 1524 pathobiology of, 1951 -1954 prevention of, 1954 prognosis for, 1954 reactional states in, 1952 -1954 skin smears in, 1953 treatment of, 1953b -1954b , 2408 tuberculoid, 1951f-1952f, 1952 in obesity, 1411 undernutrition effects on, 1389\n\nLeptomeninges, metastases of, 1253-1254, 1253f Leptospirosis, 1937 Leptospirosis, -1939 Leptospirosis, , 1966t clinical manifestations of, 1938 Leptospirosis, , 1938f definition of, 1937 Leptospirosis, -1939 Leptospirosis, diagnosis of, 1938 Leptospirosis, differential diagnosis of, 1938 Leptospirosis, epidemiology of, 1937 Leptospirosis, pathobiology of, 1937 Leptospirosis, , 1937f prevention of, 1938 Leptospirosis, -1939 , 1930 , -1935 , , 1966t acrodermatitis chronic atrophicans in, 1933 , arthritis in, 1734 , , 1932 , cardiac, 1932 , chronic, 1934 , -1935 , clinical manifestations of, 1931 , , 1932f, 1932t coinfection with, 1935 , cranial neuropathy in, 1932 , culture in, 1933 , definition of, 1930 , diagnosis of, 1933 , , 1933t differential diagnosis of, 1933 , -1934 , disseminated, 1932 , epidemiology of, 1930 , erythema migrans in, 1931 , -1934 , , 1932f, 2521 , laboratory testing in, 1933 , , 1933t lymphocytoma in, 1932 , lymphoma and, 1219 , meningeal, 1932 , , 2359t, 2369 , neurologic, 1932 , -1934 , , 2407 , pathobiology of, 1931 , , 1931f post-treatment symptoms in, 1934 , prevention of, 1935 , reinfection in, 1935 , skin examination in, 1933 , treatment of, 1934b , , 1935t Lymph nodes, 220-221, 1107 aspiration/biopsy of, 1108 on chest radiography, 520, 520t enlargement of. 2015 , 2017 transmission of, 2013 in traveler, 2013 , 2017 -2018 treatment of, 2011 -2012 , 2016b -2017b , 2016t antibacterials in, 2017 artemether in, 2012 , 2016t-2017t, 2017 artesunate in, 2012 , 2016t-2017t, 2017 atovaquone in, 2011 , 2017 chloroquine in, 2011 , 2016 , 2016t doxycycline in, 2011 , 2016t halofantrine in, 2016 -2017 lumefantrine in, 2012 , 2016 -2017 , 2016t-2017t mefloquine in, 2011 , 2016 -2017 , 2016t-2017t primaquine in, 2011 , 2016t, 2017 proguanil in, 2011 , 2016t, 2017 quinidine in, 2012 , 2016t, 2017 quinine in, 2012 , 2016t sulfadoxine-pyrimethamine in, 2017 , 2017t uncomplicated, 2015 vs. viral hemorrhagic fever, 2153t Malathion, 2080b , 2547 Maldigestion, 1388 , 1388t, 1405 2360 syphilitic, 1925 , 1927 treatment of, 2361b -2365b , 2362t-2363t ventriculitis in, 2356 -2357 vs. viral meningitis, 2367 , 2367t cancer-related, 2369 Candida, 1988 -1990 chemical, 2320 -2321 , 2369 vs. bacterial meningitis, 2360 chronic, 2370 chronic, 2368 -2369 , 2369t infectious, 2369 intermittent, 2370 noninfectious, 2369 -2370 , 2370t persistent with neutrophil predominance, 2370 , 2370t cryptococcal, 1975 , 1984 -1985 eosinophilic, 2368 -2369 , 2369t, 2371 CSF examination in, 2231t, 2359t differential diagnosis of, 2367t Lyme disease, 1932 , 2359t, 2369 Mollaret's, 2370 in Mycoplasma pneumoniae infection, 1915 noninfectious, 2368t, 2369 -2370 , 2370t protozoal, 2367t-2368t sarcoid, 2369 -2370 syphilitic, 2369 tuberculous, 1943 , 2231t, 2355 -2356 , 2359t, 2369 viral, 2365 815 Microangiopathy, thrombotic, 770 Microbiome, 200 Microcyte, 1024f Microdeletion syndromes, 191-192 Microduplication syndromes, 191-192 Micronutrients, 1397 -1406 , 1994-1997 cerebral, 1996 clinical manifestations of, 1995-1997 culture in, 1997 cutaneous, 1995-1996 definition of, 1994 diagnosis of, 1996 disseminated, 1996 epidemiology of, 1994-1995 gastrointestinal, 1996 histopathology of, 1996 pathobiology of, 1995 pulmonary, 1995, 1996f renal, 1996 rhinocerebral, 1995 risk factors for, 1994-1995 soft tissue, 1995-1996 190-192, 191f, 1340 . See also Genetic disorders and specific genes and genetic disorders autosomal dominant, 192 autosomal recessive, 192 cancer-related, 199, 200t, 1184 cardiovascular disease-related, 200t copy-number variation and, 191-192 dynamic, 191 microdeletion and, 191-192 microduplication, 191-192 nonsynonymous, 191 rate of, 196 single nucleotide, 191 transition, 191 X-linked, 192 MUTYH-associated polyposis, 1281t, 1282 MVK gene, 1671 Myasthenia gravis, 228t, 229, 2418 clinical manifestations of, 2420, 2420f diagnosis of, 2420-2421, 2421t differential diagnosis of, 2421 epidemiology of, 2418 generalized with acetylcholine receptor antibodies, 2420 with muscle-specific kinase antibodies, 2420 treatment of, 2421-2422 HLA associations in, 225t neonatal, 2418, 2419t, 2421, 2421t ocular, 2420-2421 ophthalmoparesis in, 2448 pathobiology of, 2418-2423, 2419f, 2419t prognosis for, 2422 repetitive stimulation study in, 2233\n\nMultiple endocrine neoplasia type 2A (MEN 2A) nontuberculous, 1948 -1950 clinical manifestations of, 1948 cutaneous, 1949 , 2546 definition of, 1948 , 1948t diagnosis of, 1949 -1950 , 1950f disseminated, 1948 -1949 epidemiology of, 1948 HIV infection and, 2191t-2193t, 2194 , 2222t, 2223 , 2223f lymphatic, 1949 pathobiology of, 1948 , 1949f prevention of, 1950 prognosis for, 1950 pulmonary, 1949 , 1950f rapidly growing, 1948 , 1948t slowly growing, 1948 , 1948t soft tissue, 1949 treatment of, 1950b Mycobacterium tuberculosis, 1939 -1941 . 1913 definition of, 1912 dermatologic complications of, 1914 -1915 , 1914f diagnosis of, 1915 epidemiology of, 1912 , 1912t extrapulmonary, 1914 hematopoietic complications of, 1915 musculoskeletal complications of, 1734 , 1915 neurologic complications of, 1915 pathobiology of, 1912 , 1913f prevention of, 1916 renal complications of, 1915 respiratory, 1913 -1914 , 1914f secondary prevention of, 1916 susceptibility to, 1915 treatment of, 1916b Mycoplasma pneumoniae infection, 1912 -1916 Nexavar, 1168t-1176t Next-generation sequencing, 192-193, 193f-194f NEXUS Low-Risk Criteria, 2260 , 1907 , -1908 , , 1907t-1909t treatment of, 1910 in , 132, 1638 -1639 , 1640t, 1764 , 1814t in diphtheria, 1834b Enterobacteriaceae resistance to, 1875 , 1875t in nonsyphilitic treponematoses, 1930b resistance to, 1808t in scarlet fever, 2522 in syphilis, 1927b -1928b in kidney failure, 128t pharmacokinetics of, Pertussis (whooping cough), 1900-1903, 1965t catarrhal phase of, 1901 clinical manifestations of, 1901 complications of, 1901 convalescent phase of, 1901 definition of, 1900-1902 diagnosis of, 1901-1902, 1902f epidemiology of, 1901 immunization against, 65f-66f, 67t-70t, 72, 1902 incubation period of, 1901 paroxysmal phase of, 1901 pathobiology of, 1901 prevention of, 1902 prognosis for, 1902 treatment of, 1902b , 694-696, 696f, 696t Pituitary adenoma, 1250 , 1428 , 1433 -1434 ACTH-producing, 1435t, 1440 , 1440f, 1440t-1441t, 1465 after bilateral adrenalectomy, 1442 clinical manifestations of, 1433 , 1435t gonadotropin-producing, 1435t, 1443 growth hormone-producing, 1435t, 1436 -1437 , 1436f, 1437t hypogonadism with, 1524 hypopituitarism with, 1432 -1434 infarction with, 1433 in MEN 1, 1506 nonfunctioning, 1435t, 1444 pathobiology of, 1433 prolactin-producing, 1435t, 1438 , 1524 TSH-producing, 1435t, 1444 1998 -1999 , 2201 -2202 definition of, 1997 diagnosis of, 1999 , 1999f-2001f, 2201 -2207 , 2203f, 2205f differential diagnosis of, 2000 drug-resistant, 2003 epidemiology of, 1998 ground-glass opacities in, 2203 -2204 , 2204f HAART therapy and, 2003 -2004 imaging in, 2203 -2204 , 2203f-2206f immune reconstitution inflammatory syndrome and, 2222t, 2223 , 2224f vs. nonspecific interstitial pneumonitis, 2207 -2208 pathobiology of, 1998 prevention of, 2003 -2005 , 2191t-2193t, 2193 -2194 prognosis for, 2005 treatment of, 2000b -2003b , 591b-593b, 592t, 1766 viral, 589-591, 593 in compromised host, 1778t, 1779 fungal Blastomyces, 1981 Coccidioides, 1980 , 1980f Mucorales, 1995 , 1996f Nocardia, 1970 , 1971f health care-associated, 594-596, 1784 clinical manifestations of, 595 diagnosis of, 595 epidemiology of, 594, 594t pathobiology of, 594-595 prevention of, 596 Staphylococcus aureus, 1818 treatment of, 595b-596b, 595t lipoid, 580-581, 581f Mycoplasma pneumoniae, 1912 Mycoplasma pneumoniae, -1916 Mycoplasma pneumoniae, clinical manifestations of, 1913 Mycoplasma pneumoniae, , 1913f-1914f diagnosis of, 1915 Mycoplasma pneumoniae, epidemiology of, 1912 Mycoplasma pneumoniae, extrapulmonary complications of, 1914 Mycoplasma pneumoniae, , 1914f pathobiology of, 1912 Mycoplasma pneumoniae, prevention of, 1916 Mycoplasma pneumoniae, treatment of, 1916b Mycoplasma pneumoniae, occupation-related, 568t pain in, 247t, 834t-836t pneumococcal, 1820 2007 Mycoplasma pneumoniae infection, 1916 myocardial infarction, 170, 170t, 174, 175t-176t, 446-448, 447f, 447t Neisseria meningitidis, 1854 -1855 , 2532 , 2532f, 2544 -2546 Pseudomycetoma, 2006 -2007 Pseudoporphyria, 2528 Pseudothrombocytopenia, 1122 -1125 Pseudothrombophlebitis, 1680 , 1684 -1685 Pseudotumor, orbital, 2430 , 2440 Pseudoxanthoma elasticum, 935, 1666 -1667 , 2537 -2538 acquired, 1667 Psilocybin abuse, 158 Psittacosis, 84t, 1921 -1922 vs. viral hemorrhagic fever, 2153t Psoas sign, 837t Psoriasis, 2505 Psoriasis, , 2505f, 2507 Psoriasis, , 2508f, 2517 1908, 1908t-1909t, 1956t, 1958 , 1985-1986 clinical manifestations of, 1985-1986 definition of, 1985 diagnosis of, 1986 epidemiology of, 1985 lymphocutaneous, 1985, 1986f osteoarticular, 1985-1986 pathobiology of, 1985 prognosis for, 1986 treatment of, 1986b visceral, 1985-1986 , 1798 , , 1922 , -1929 , cardiovascular, 1925 , chancre of, 1923 , -1924 , , 1923f, 2546 , CNS, 1925 , , 1925t, 1927 , , 1929 , condylomata lata in, 1923f, 1924 , congenital, 1926 , -1928 , dark-field examination in, 1926 , definition of, 1922 , diagnosis of, 1926 , , 1926t differential diagnosis of, 1927 , endemic, 1929 , -1930 , epidemics of, 1923 epidemiology of, 1923 false-positive tests for, 1927 follow-up examinations in, 1929 granulomatous reaction in, 1924 gummas in, 1925 hepatitis in, 1924 HIV infection and, 1925 -1926 , 2198 , 2210 , 2210f Jarisch-Herxheimer reaction in, 1928 late, 1924 -1925 , 1925t latent, 1924 meningeal, 1925 , 2359t meningoencephalitic, 1925 meningovascular, 1925 musculoskeletal manifestations of, 1735 natural course of, 1923 , 1923f pathobiology of, 1923 in pregnancy, 1928 prevention of, 1929 primary, 1924 prognosis for, 1929 rash in, 1923f, 1924 relapsing, 1924 screening for, 54t secondary, 1924 , 2436 , 2520 , 2520f, 2546 serologic tests for, 1926 -1927 , 1926t spinal, 1925 treatment of, 1927b -1928b 1931, 1931f prevention of, 1801, 1895, 1957, 2049, 2078-2079 prophylaxis after, 2079 in relapsing fever transmission, 1936 in rickettsioses, 1955-1962, 1955t, 2078 tick removal after, 1957f 1866 -1867 Toxocariasis, 990t-992t, 2069 -2076 , 2069t covert, 2069 Toxoplasma gondii, 2030 -2032 , 2031f Toxoplasmosis, 1966t, 2030 -2038 cerebral, 2195 clinical manifestations of, 2032 -2033 , 2033f-2034f, 2033t congenital, 2032 -2033 , 2033t, 2034f, 2035 , 2037t definition of, 2030 , 2031f diagnosis of, 2033 -2035 , 2034t epidemiology of, 2031 hepatic, 990t-992t in HIV-infected patient, 2032 , 2035 -2036 , 2191t-2192t, 2195 , 2204 in immunocompromised host, 2035 -2037 , 2191t-2192t lymphadenopathy in, 2032 -2033 , 2035 myocardial, 325 ocular, 2035 , 2037 , 2435 pathobiology of, 2032 pathology of, 2032 post-transplantation, 2032 , 2035 in pregnancy, 2032 , 2035 -2036 , 2037t prevention of, 2036 -2037 , 2191t-2193t, 2194 prognosis for, 2037 reactivation of, 2032 -2033 , 2033t, 2036t retinal, 2195 , 1907 -1908 , 1907f, 1907t-1909t treatment of, 1910 Treponema carateum infection, 1929 -1930 Treponema pallidum, 1922 -1924 Syphilis; Yaws Treponema pallidum particle agglutination (TP-PA) test, 1926 -1927 , 230, 1944 in HIV infection, 1944 , 2201 Tuberculosis, 1939 -1948 abdominal, 1943 active, 1944 -1945 arthritis in, 1734 -1735 chest radiography in, 590, 590f in children, 1945 clinical manifestations of, 1941 , 1942f-1943f colonic, 924-925 cutaneous manifestations of, 2546 definition of, 1939 diagnosis of, 1944 drug-resistant, 1782 , 1940 , 1945b -1946b , 1947t epidemiology of, 1940 , 1941t extrapulmonary, 1941 , 1942f, 1943 gastrointestinal, 1943 -1944 Ghon complex in, 1941 , 1942f hepatic, 995, 995t HIV infection and, 2191t-2192t, 2194 , 2201 -2203 , 2202f-2203f, 2208 , 2222 -2223 , 2222t latent, 1940 lymphatic, 1943 meningeal, 1943 , 2231t, 2355 -2356 , 2359t, 2369 miliary, 1943 , 1943f, 1945 occupational transmission of, 1787 pathobiology of, 1940 pericardial, 475t, 481, 1943 peritoneal, 926, 1943 pleural, 610, 1941 , 1943 prevention of, 1947 primary, 1940 -1941 prognosis for, 1947 progressive primary, 1941 Ranke complex in, 1941 reactivation (postprimary), 1941 -1942 biologic response modifiers and, 1779 reinfection, 1943 renal, 1944 risk factors for, 1940 , 1941t screening for, 54t small intestine, 924-925 treatment of, 1945b -1946b , 1947t duration of, 1813 uveal, 2436 vertebral, 1944 Tuberous sclerosis, 796t, 2390 , 1956t, 1959, 1966t murine, 1956t, 1959-1962 scrub, 1956t, 1960 vs. viral 887-888, 888t genital, 1797t, 1798 887-888, 888t genital, 1797t, , 1927 887-888, 888t genital, 1797t, Mooren's, 2440 887-888, 888t genital, 1797t, oral, 2449 887-888, 888t genital, 1797t, , 2449t, 2450f pressure, 109, 109f syphilitic, 1798 887-888, 888t genital, 1797t, , 1923 887-888, 888t genital, 1797t, -1924 887-888, 888t genital, 1797t, , 1923f, 2500 887-888, 888t genital, 1797t, , 2546 1721-1722, 1721t leukocytoclastic, 1196t, 1722t, 1726, 2525, 2525f, 2533 drug-related, 2535 medium-vessel, 1721t, 1722-1726, 1723f, 1724t neuropathic, 2404, 2405t nodular, 2541, 2542f paraneoplastic, 1199 Verruga peruana, 1906 Verruga peruana, , 1908t-1909t, 1909 treatment of, 1134 , 1135t Voriconazole, 1975 adverse effects of, 1975 in aspergillosis, 1975 , 1993b -1994b , 1993t drug interactions with, 1975 formulations of, 1975 "}